Sterilization vaccine for Kangaroos - immunocontraception for people next?

Author Topic: Sterilization vaccine for Kangaroos - immunocontraception for people next?  (Read 6124 times)

0 Members and 1 Guest are viewing this topic.

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
think development of  "FRV = Fertility Regulating Vaccines"

http://debatepedia.idebate.org/en/index.php/Argument:_Sterilization_vaccines_can_be_used_instead_of_killing_Kangaroos
Argument: Sterilization vaccines can be used instead of killing Kangaroos

Kangaroo Culling on Defence lands – Fact Sheet" - "Defence is implementing an experimental form of fertility control at the fenced Belconnen Naval Transmitter Station, based on research by a partnership involving the University of Newcastle and ACT Parks, Conservation and Lands. The research is aimed at developing a species-specific, orally delivered immunocontraceptive vaccine for eastern grey kangaroos. The vaccine is expected to provide sterility for at least three years." Sterilizing kangaroos is the most humane way to curb population growth.

The Technology: (notice from NIH) :

http://www.ncbi.nlm.nih.gov/pubmed/19215986
Immunocontraception of Eastern Grey kangaroos (Macropus giganteus) with recombinant brushtail possum (Trichosurus vulpecula) ZP3 protein.

Kitchener AL, Harman A, Kay DJ, McCartney CA, Mate KE, Rodger JC.


Source

Cooperative Research Centre for Conservation and Management of Marsupials, School of Environmental and Life Sciences, University of Newcastle, Callaghan, NSW 2308, Australia.


Abstract

This study examined the potential of a recombinant marsupial zona pellucida 3 protein as a contraceptive vaccine for the Eastern Grey kangaroo, a marsupial that is locally overabundant in several regions of eastern Australia.

First, a pilot study using porcine zona pellucidae (PZP) demonstrated that ZP proteins, primarily the ZP3 component of PZP, are highly immunogenic in the grey kangaroo and produce a long-lasting humoral response to a single immunisation, as found in other marsupials.

Immunisation with 300 microg of a non-glycosylated recombinant brushtail possum ZP3 (recBP-ZP3) protein in complete Freund's adjuvant produced a similar, significant and sustained antibody response, and none of the immunised kangaroos (n=7) produced offspring during the following breeding season compared with four out of the six control animals. An epitope analysis of the B-cell response to recBP-ZP3 using a brushtail possum ZP3 identified numerous B-cell epitope regions clustered around the N- and C-terminal regions of the protein.

Two regions of interest for further fertility vaccine development based on their immunogenicity and fertility trials and functional studies in other species were found to be immunogenic. These results suggest that immunocontraception based on targeting the ZP3 protein within the zona pellucida may be an effective strategy for fertility reduction in Eastern Grey kangaroos.

| - - - -

http://en.wikipedia.org/wiki/Freund's_adjuvant

Freund's adjuvant is a solution of antigen emulsified in mineral oil and used as an immunopotentiator (booster). The complete form, Freund's Complete Adjuvant,(CFA or FCA) is composed of inactivated and dried mycobacteria (usually M. tuberculosis), whereas the incomplete form (IFA or FIA) lacks the mycobacterial components (hence just the water in oil emulsion). It is named after Jules T. Freund.
...
Its use in humans is forbidden by regulatory authorities, due to its toxicity. Even for animal research there are currently guidelines associated with its use, due to its painful reaction and potential for tissue damage. Injections of CFA should be subcutaneous or intraperitoneal, because intradermal injections may cause skin ulceration and necrosis; intramuscular injections may lead to temporary or permanent muscle lesion, and intravenous injections may produce pulmonary lipid embolism.

http://www.wikigenes.org/e/gene/e/396927.html

ZP3  -  zona pellucida glycoprotein 3

http://www.biolreprod.org/content/45/5/727.full.pdf
BIOLOGY OF REPRODUCTION 45, 727-735 (1991)

Blocking of Human Sperm-Zona Interaction by Monoclonal Antibodies to a Glycoprotein
Family (ZP4) of Porcine Zona Pellucida1


http://www.pzpinfo.org/pzp.html
Porcine Zona Pellucida Vaccine

What is PZP and How Does It Work?
A non-cellular membrane known as the zona pellucida (ZP) surrounds all mammalian eggs. The ZP consists of several glycoproteins (proteins with some carbohydrate attached), one of which, ZP3, is thought to be the sperm receptor (the molecule which permits attachment of the sperm to the egg during the process of fertilization).

The PZP vaccine is derived from pig eggs. When this vaccine is injected into the muscle of the target female animal, it stimulates her immune system to produce antibodies against the vaccine. These antibodies also attach to the sperm receptors on the ZP of her own eggs and distort their shape, thereby blocking fertilization (see Paterson and Aitkin 1990).

Thus far PZP has been a promising form of contraception in wildlife because

1. it has prevented pregnancy an average of 90% of the time in treated animals
2. it can be delivered remotely by small darts
3. the contraceptive effects are reversible
4. it is effective across many species
5. there are no debilitating health side-effects even after long-term use
6. it has almost no effects on social behaviors
7. the vaccine cannot pass through the food chain
8. it is safe to give to pregnant animals (see Kirkpatrick et al. 1996b).

How is the Vaccine Delivered?
The PZP vaccine must be injected into the muscle of the target animal. This can be done by hand if the animal is restrained, or by dart, for remote delivery. There are many commercial dart systems available but the thick viscosity of the vaccine requires a large needle and a quick injection. Thus far, Pneu-Dart(r) systems (Williamsport, PA) seem to work the best. The Pneu-Dart(r) 1.0 cc barbless darts can be fired from Pneu-Dart(r) capture guns or from several other commercial dart guns (Pax-Arms(r) or Dan-Inject(r), for instance). The darts are disposable, and after hitting the animal in the rump or hip (the only acceptable location for darting) they inject by means of a small powder charge and pop out. Because of their bright colors the darts are usually retrieved in the field. Undischarged darts cannot be discharged by stepping on them or by any other kinds of casual contact. Over a ten year period on Fire Island National Seashore, and more than 1,500 dartings of deer, only 6 darts have not been recovered.

Normally, each animal is darted twice the first year, with the first injection being given up to a year before a booster, just preceding the breeding season (March for wild horses or September for deer). Thereafter, a single annual booster inoculation will maintain contraception. The second inoculation of the first year requires

1. that you are able to recognize the individual animals, or
2. that you do the first inoculation with a special "marker dart" which leaves a dye mark on the animal at the same time it injects the vaccine, or
3. that animals are treated opportunistically and randomly, with the hope of eventually treating a large proportion of the total population over the course of several years.

An alternative strategy is to give only a single inoculation the first year, from which there will be little contraception, and then a single annual inoculation thereafter, from which there will be significant contraception (see McShea et al. 1997). Current research is aimed at the development of an effective and longer acting one-inoculation form of the vaccine (see Turner et al. 2002).

http://www.jrijournal.org/article/S0165-0378(99)00063-7/abstract

Possible mechanisms of mammalian immunocontraception
accepted 29 November 1999.
A conundrum has risen where pZP, a single vaccine, successfully induces an immunocontraceptive effect in multiple species of mammals. This review describes the most current data pertaining to the mammalian zona pellucida and immunocontraception, and from these studies, we suggest several potential mechanisms of immunocontraception.


[ As a note these injections sound very much like the small pox vaccine or any other muscle injected vaccine... ]

Notice they will be allow you to be fertile or make you sterile....

http://www.bioscience.org/u37153137/gaDTRQo7632rgysaGWQYT64356/2007/v12/af/2191/2191.pdf
Frontiers in Bioscience 12, 1833-1844, January 1, 2007]
Peptide vaccines against cancer, infectious diseases, and conception
Rajesh K. Naz and Pankaj Dabir

Antibodies to ZP3 or its peptide fragments block fertilization (73, 74). Active immunization of female
animals of various species, including primates, with ZP3 or its peptide fragments induces infertility
(75-79).

However, immunization with the whole ZP3 molecule generally causes irreversible oophoritis with loss of primordial
follicles
and decrease of estrogens, leading to premature ovarian failure (POF).

Sperm peptides
Several sperm peptides have been delineated and are being explored for vaccine development (Table 2).
Notable among are discussed below.
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
http://ki.se/content/1/c6/11/28/47/Tempe.pdf
Fertility as a disease? Family planning policies in India and research on immunocontraceptives[/b]
...
This paper attempts to describe and critically analyse the research and controversies surrounding the anti-fertility vaccines, or “immunocontraceptives”, with focus on the anti-hCG vaccines developed by the National Institute of Immunology, New Delhi, and the Special Programme of Research, Development and Research Training in Human Reproduction (HRP) of WHO.
...

IMMUNOCONTRACEPTIVES
Background

Already in the 1930s the idea of using the immune response of humans as a mean of controlling fertility was being explored by scientists. However, it was first in the 1960s that researchers realised that some forms of infertility can be caused by the action of the immune response in women or men against sperm. The research on immunocontraceptives, also called anti-fertility vaccines, was started by a number of medical research institutions in the early 1970s.

The stated aim of the research was to develop a contraceptive that would have no adverse pharmacological effects, that would be effective for two years, be easy to administer, cheap to produce and highly acceptable to individuals. During the 1980s and 1990s there were five research centres conducting the main part of the research on immunocontraceptives:

- The National Institute of Immunology, New Delhi, India
- The Special Programme of Research, Development and Research Training in Human Reproduction (HRP) of the WHO, Geneva, Switzerland
- The Population Council, New York, USA
- The Contraceptive Research and Development Program (CONRAD), Norfolk, USA
- The National Institute of Child Health and Development of the National Institutes of Health (NICHD/NIH), Bethesda, USA

Principles of the immunocontraceptives

The basis for all research on immunocontraceptives has been to find a way of eliciting antibody-response to a target-antigen that is crucial for the fertilisation process. Many such target-antigens have been proposed and they have mainly had hormonal origin. This has been the case in the research on vaccines against FSH, GnRH and hCG (human chorionic gonadotropin). Other types of antigens have been proposed which are accessible on the cell surface of the sperm and oocyte. It is the anti-hCG vaccine which has been developed the furthest of the vaccines mentioned above and therefore I will focus will be on this type of immunocontraceptive.

Regular vaccines, which aim at protecting an individual from a potential disease, all use antigens that are foreign to the body in order to elicit an efficient immune response. There is one crucial difference between these regular vaccines and the immunocontraceptives – namely the fact that in the latter case the immune response is triggered into acting on a self-antigen, i.e. a substance normally found in the body (for example the hormones GnRH and FSH). Under normal circumstances the immune system does not act against self-antigens in the body, a phenomena known as “self-tolerance”. However, when the self-tolerance is disturbed there is a risk that the individual will develop autoimmune disease, for example rheumatoid arthritis or SLE etc. This has been one of the main concerns when developing an immunocontraceptive – the risk of inducing autoimmune disease as a result of using a self-antigen to trigger the immune response.
...
http://www.youtube.com/watch?v=ZBVqblu_GuQ

The WHO is having a hard time pushing their polio vaccines in Nigeria, Pakistan, and other countries since it was discovered that some batches contained hormones that act as sterilants, as well as cancer-causing viruses and other materials that have left many children permanently damaged.
Do these things happen by accident or is this part of a deliberate attempt to reduce population growth?


http://www.youtube.com/watch?v=R005vkMmk1s
IMMUNOCONTRACEPTIVE HIDDEN IN THE FLU VACCINE Sep 1, 2009


http://www.biotech-monitor.nl/2502.htm
Challenging  the  Immune  System: The development of anti-fertility vaccines
By Ute Sprenger -Dec 1995 -

Over recent decades, researchers have been exploiting new contraceptive methods to use in family planning programmes in the South. Within the scope of medical application of modern biotechnologies, the development of anti-fertility vaccines is a new approach. However, these new vaccines do not really benefit the user, says Ute Sprenger.

Modern biotechnologies in the health care sector not only serve as a basis for prevention, new diagnostic methods and cures for diseases. They also make intervention into the domain of human reproduction possible through the development of a variety of new methods and products to control fertility. While the significance of artificial insemination is negligible for the majority of people in the South, the possibility to prevent pregnancy is of major importance. Many advocates of population control policy envisage anti-fertility vaccines, once on the market, as a promising contraceptive. Unlike conventional methods, such as the intra-uterine device, the pill, hormone injections and implants, contraceptive vaccines use the immune system to induce antibodies against hormones or other molecules involved in human reproduction. Although these vaccines can be used by both men and women, most of the research is directed towards women, as scientists perceive the female cycle to be the easiest target.  

Proponents of anti-fertility vaccines claim that they offer a wider choice of family planning methods. However, from a user’s perspective two questions need to be answered: (1) does this new technology empower women to gain more autonomy over their fertility?; and (2) does it improve their health?

Strategy
Over the last two decades world wide research on fertility regulating vaccines has been conducted under the auspices of the World Health Organization (WHO). Some prototype vaccines have undergone or are currently undergoing clinical trials in several countries. The entirely new immunological approach is based on the idea that a long-term contraceptive method, intended for use in family planning programmes in countries with low levels of medical care, should require little motivation of the user, should be cheap, and should be simple to apply by the provider.

The approach is an integral part of the strategy of demographic control, which has provided a series of long-lasting, provider-dependent birth control methods since the 1960s.

At a 1989 WHO symposium on the safety and efficacy of anti-fertility vaccines the chairman summarized the debate: "Foremost in my mind during these discussions was our difficulty in assessing the urgency of the demographic crisis. To the extent that the impact of that crisis increases, the need for more effective family planning technologies must increase. At the very least, failure to develop something that may provide a more effective technology would be to take a grave and unnecessary risk."

Approaching the hormonal cascade

The anti-fertility vaccines that are being researched refer to the mode of action of conventional vaccines against diseases. They are based on the stimulation of the immune system, but unlike anti-disease vaccines which target foreign substances, anti-fertility vaccines evoke antibodies against the body’s own substances like molecules. As a result, the body’s self-protection is reprogrammed to attack targets the body normally tolerates. To that end, the targeted, normally tolerated molecule, has to be linked to a foreign protein, rendering the entire product ‘foreign’ and inducing an antibody reaction.

Currently six variations of these vaccines are at different stages of development. Commonly identified as the most suitable candidates for vaccine development are certain molecules on the surface of the sperm and the egg, molecules on the surface of the fertilized egg and the early embryo, and human chorionic gonadotrophin (hCG). The hormone hCG is secreted by the surface of the early embryo to remain implanted in the womb. If hCG is blocked, the level of progesterone declines and the blastocyst (fertilized egg 5 days after fertilization) is expelled, thereby terminating the pregnancy. Anti-hCG vaccine consists of a part of the hormone linked to a bacterial or viral carrier inducing the antibody reaction. However, researchers admit that it is not known exactly how immunization against hCG impairs fertility.

The prototype version of an anti-hCG vaccine consist of an immunogen, formed from a (synthetic) peptide of hCG conjugated to a toxoid carrier molecule, mixed with an immunostimulant, and suspended in a fluid vehicle.

Other more advanced approaches that have reached clinical trials are vaccines inhibiting the gonadotrophin-releasing hormone (GnRH), produced within the diencephalon. The diencephalon (hypothalamus) is a part of the brain that lies beneath the thalamus where the flow of steroid hormones is regulated. The hormone is involved in the fine-tuning of these steroid hormones. Because this vaccine, developed by the Population Council, brings the hormonal cascade to a total standstill both male and female recipients need  synthetic steroid hormone replacement in order to counteract unwanted side-effects such as the loss of bone density. In women a reaction similar to an artificial menopause is induced.

The first clinical trials with anti-fertility vaccines began in the 1970s.

Until early 1994, about 400 experimental subjects, mainly women, were involved. By far the most researched and clinical tested are anti-hCG vaccines.

 Two prototypes, developed by National Institute of Immunology (NII) and the Special Programme of Research, Development and Research Training in Human Reproduction (HRP),

 are being tested on women in India, Australia, Brazil, Chile, Dominican Republic, Finland and Sweden. The NII has started experiments with live vectors. In order to prolong antibody response
, beta-hCG genes were transferred into a vaccinia virus [ SMALL POX!!!,
 which reproduces itself. The stability of the vaccinia, pathogen of cowpox, is controversial.
 
...
Actors involved
In the early 1970s a group of scientists came together at the WHO to discuss the impact of the advances in biosciences on birth control.

In 1973 the WHO established the Task Force on Vaccines for Fertility Regulation, as part of the HRP.

The HRP, today under the auspices of the United Nations Development Programme, the United Nations Population Fund (UNFPA), the WHO and the World Bank, concentrates on research and development of contraceptive methods and services in developing countries and its social, ethical, legal and regulatory issues.

The Task Force acts as a global coordinating body for anti-fertility vaccine R&D in the various working groups and supports research on different approaches, such as anti-sperm and anti-ovum vaccines and vaccines designed to neutralize the biological functions of hCG. The Task Force has succeeded in developing a prototype of an anti-hCG-vaccine.

Currently five large and a number of small institutions are conducting research on anti-fertility vaccines. The five large institutions involved are:

WHO/HRP, Switzerland. Major supporters of the programme are the governments of Sweden, United Kingdom, Norway, Denmark, Germany and Canada, as well as the UNFPA and the World Bank.

The Population Council, United States. Among the Council’s financiers are the Rockefeller Foundation, the National Institutes of Health and the US Agency for International Development.

National Institute of Immunology, India. Major financiers are the Indian government, the Canadian International Development Research Centre and the Rockefeller Foundation.

The Contraceptive Development Program (CONRAD), United States. Publicly funded.

The Center for Population Research at the National Institute of Child Health and Development/the National Institutes of Health (NICHD/NIH), United States. Publicly funded.

Various smaller research teams conducting basic, pre-clinical research and clinical trials with anti-fertility vaccines are based at universities in Kenya, Germany and France, or at institutes like the Medical Research Council (MRC) in England. They receive public funds or are supported by pharmaceutical companies such as Schering (Germany) or Organon (the Netherlands).

According to WHO/HRP, of the approximately US$ 57 million spent annually on overall contraceptive research, an estimated 10 per cent is devoted to anti-fertility vaccines. WHO/HRP figures indicate an expenditure of US$ 946,000 or 16.3 per cent of the programme budget in 1992. According to David Griffin, manager of HRP Vaccines Task Force, the Programme has spent approximately US$ 10 to 11 million on anti-fertility vaccines between 1973 and 1993.

Hazards

The following hazards concerning contraceptive vaccines have been suggested:

Auto-immune disorders and cross-reactivity. In order to achieve immuno-contraception, the body’s mechanism of self-protection must be induced to attack the molecules on the sperm, eggs or hormones. Though researchers involved emphasize that until now no side-effects or unintended reactions of the immune system have occurred, it can not be excluded that allergic reactions, cross reactions on others then the target-cell or molecules, or auto-immune diseases might appear in the medium or long-term. After all, the immune system is an open system that weakens with stress, injuries, illness, and age.

Normally the immune system distinguishes between what immunologists call "self" and "non-self": it tolerates the body’s own substances like tissue, cells, proteins and attacks foreign substances. However, since the 1960s the number of diseases of "unknown etiology" classified as immune-system-related diseases has been increasing. An estimated two-thirds of the adults in Europe and North America suffering from an auto-immune disorders are women. Particularly in view of an increase in immune-related diseases it may be risky to manipulate the highly complex mechanism of "self" tolerance of the human organism.

Moreover, there is a possibility of a cross-reactivity of vaccine candidate antibodies with other hormones. For instance, the hormone hCG is a member of the family of glycoprotein hormones, which also includes lutropin (LH), follitropin (FSH) and thyrotropin (TSH). Parts of the structure of these four hormones are similar, so that antibodies elicited against hCG may interfere with other pituitary hormones. Some experts have also warned of a risk of an auto-immune attack against the ovaries. Unexpected cross-reactivity has already been observed against pancreatic cells.

Other unexpected side-effects. Trials under the auspices of WHO/HRP at the Karolinska Hospital in Stockholm, Sweden were suspended in June 1994. According to a programme document, the first seven volunteers to receive the vaccine all experienced totally unexpected side-effects which included pain at the injection site, fever and sterile abscess formation. The Task Force researchers suspect batch related causes and are investigating the material to eliminate side-effects.

Medical needs. Even if the technology itself gets more sophisticated and some of the medical problems can be solved, the danger remains that anti-fertility vaccines will be used in regions lacking the necessary medical care. Angeline F. Schrater, women’s health advocate, describes the imperative structural medical needs of anti-fertility vaccines as follows: "Women must be screened for pregnancy before immunization and monitored for protective immunity after. They also must be tested for allergic reaction to the vaccine prior to each injection. Further, reversibility cannot be guaranteed and women must be so informed."

Abuse. Due to the lack of user control, the approach also bears a high potential for abuse. The method might encourage efforts to control female fertility for demographic purposes as it is easy for medical or paramedical staff to administer without a woman’s full knowledge or consent. The design of anti-hCG vaccines allows the antagonist to be coupled with vaccines against diseases, i.e. diphtheria, tetanus or measles. As admitted at the 1989 WHO-Symposium, due to this potential for abuse, the method might even discredit health care and general vaccination programmes conducted in countries of the South.

Duration. It is generally assumed that the final product will be a anti-fertility vaccine, administered by injection or orally and lasting for one to two years. Once the treatment is administered it cannot be discontinued and women or men affected must wait until the immunological effect decreases. Though the WHO/HRP is considering counter-vaccines to "switch on" fertility if required, nothing concrete has been researched so far.

In fact, when and whether fertility is regained depends not only on the individual immune response, but also on the ethnic response.

Within the scientific community there is debate about irreversibility and thus "non-surgical sterilization" as appreciated effect.

Working. Clinical trials with women have shown that the differences in immune response is not only relevant concerning reversibility but for the effectiveness of the contraceptive as well. Thus it is reported that women in clinical trials with the Indian made prototype conceived and some even gave birth to children. Yet nothing is known about the possible ill-effects on the children of these vaccinated women, and no research on this is being carried out.

Protests
More than twenty years after researchers began to investigate the use of antibodies for contraceptive purposes, many related questions concerning efficacy, safety and the ability to meet women’s needs, remain unanswered. Additionally, by supporting a practice based on population policy they are likely to undermine women’s rights for reproductive self-determination.

During the last decade, in many Southern countries demographic targets were introduced, and field workers and para-medical staff are stimulated to distribute effective contraceptives to reduce the birth rates. Long-term, provider-dependent methods are seen as most suitable to meet these requirements. Considering that there seems to be a growing tendency to oblige poor women from the South to control their fertility, it is doubtful whether such a climate has stimulated the right of women to determine their family planning methods, or even whether they want to use contraceptives at all.

Certainly, women and men need access to safe and convenient methods of birth control as well as safe methods of abortion. But will women, being at the receiving end of modern contraceptive R&D yet again, be content with this new kind of provider-dependent and invasive vaccine? Many may not, as shown by the appeal of more than 400 groups advocating women’s health, from about 40 countries (including Australia, Chile, Germany, India, USA and Zimbabwe). They recently called for the termination of research on anti-fertility vaccines, and for a re-orientation of contraceptive research, away from the technology fix. Instead of demographic considerations directing contraceptive research, the research should enabling people to gain control over their own fertility.
Ute Sprenger

Burgsdorfstrasse 11
13353 Berlin, Germany

Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
http://www.finrrage.org/pdf_files/Conference%20Reports/ImmunologicalContraceptives.pdf

Workshop on Immunological Contraceptives (Antifertility ‘Vaccines’), 7th International Women
and Health Meeting, Kampala,Uganda, 12-l8th September 1993
CLINICAL TRIALS OF IMMUNOLOGICAL CONTRACEPTIVES
Judith Richter

Funding:
Pop. Council’s “programmatic funds”
(i.e. George J.Hecht Fund : The Andrew W.Mellon Foundation : The Rockefeller Foundation).

PRE-CLINICAL RESEARCH
Before mentioned five organisations are moreover doing laboratory and/or animal studies on:

- Anti-GnRH contraceptive, clinical trial planned by NICHD
- Anti-sperm contraceptives - mainly for women (CONRAD, NICHD. NII, Pop. Council).
John Herr, Virginia University, planning human trials in 1995 depending on outcome
animal trials (funding: CONRAD)
- Anti-egg immune contraceptive (CONRAD, NII)
- Anti-trophoblast contraceptive (WHP/HRP)

...
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
for those unfamiliar:

SDT - The Second Demographic Transition - One in five childbearing women childless (double from 1 in 10)

http://www.foodconsumer.org/newsite/Non-food/Lifestyle/one_in_five_childbearing_women_childless_2606101047.html
One in five childbearing women childless

About 20 percent of child-bearing women choose to be childless today compared to 10 percent in the 1970s, according to a new study.

Also:

Co-Creator of the Pill Laments Resulting Demographic "Horror Scenario"
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Quote
Funding:
Pop. Council’s “programmatic funds”
(i.e. George J.Hecht Fund:
The Andrew W.Mellon Foundation:
The Rockefeller Foundation).

Who was George J.Hecht ??? And why does he want to sterilize me?

( I swear I can't find a single photo of this Rockefeller eugenics stooge ! )

http://www.time.com/time/magazine/article/0,9171,935506,0
"There are magazines exclusively devoted to the raising of cattle, dogs and flowers, but none to the most important work in the world—raising children." With this observation, in 1926, a 30-year-old Manhattan bachelor launched Children—the Magazine for Parents. For his monthly, Publisher George J. Hecht,who combed the birth statistics for his mailing list, set a circulation of 100,000 as his wildest dream. It soon came true—and then some.

Last week Publisher Hecht, now 54, and the father of two teen-age children himself


http://en.wikipedia.org/wiki/Parents_(magazine)
Parents (magazine)

The magazine was started by George J. Hecht in 1926. It was sold to Gruner + Jahr in 1978, at which time Elizabeth Crow became the magazine's editor for the next decade.

http://www.popcouncil.org/pdfs/jadelle_monograph.pdf
...

Norplant capsule and Jadelle rod research and development were supported by several government agencies, foundations, and individuals:

the United States Agency for International Development (USAID) and
the International Development Research Centre of Canada;
the Ford Foundation,
the Andrew W. Mellon Foundation,
the Rockefeller Foundation,
the George F. Jewett Foundation,
the General Service Foundation,
and the estate/charitable trust of Abby R. Mauzé;
the United Nations Population Fund (UNFPA);
Mr. George J. Hecht (and, after his death, the George J. Hecht Fund) and
several members of the Rockefeller family;

....

Research and development

The research and development program that produced contraceptive implants—the implants had no
brand names until they became products much later—began in 1966 in the Population Council’s
biomedical research laboratories when scientists initiated laboratory investigations on the release of
steroid hormones from silicone rubber capsules.


Their results showed that the continuous release of hormones could be sustained for long periods, and
that hormonal effects in animals could be maintained for over a year. These results formed the basis
of the implant concept: that an appropriate contraceptive steroid, placed under the skin in silicone tubing,
could provide effective contraception for many years, and that a single act of contraceptive acceptance
could replace more than a thousand days of pill taking (Segal 1983; International Development Research
Centre 1990).

By late 1974, studies had been started in humans of a six-capsule contraceptive drug delivery
system. Several synthetic hormones were compared  and evaluated. The next year a randomized clinical
trial testing implants containing three different hormones was initiated in six countries (Brazil, Chile, Denmark, Dominican Republic, Finland, and Jamaica). A six-capsule implant system containing levonorgestrel emerged as the best of the three, on
the basis of effectiveness, clinical acceptability, and safety. The drug’s safety was supported by extensive
animal studies and by large-scale human studies conducted by Wyeth-Ayerst Laboratories, which
marketed oral contraceptives containing levonorgestrel.

http://theothermccain.com/2010/05/08/the-pill-at-50-unhappy-un-birthday/
...
To raise the public’s consciousness about the threat of overpopulation . . . the population movement undertook a concerted public relations campaign through a steady stream of books, pamphlets, and magazine and newspaper articles. This campaign was aided by the involvement of key publishers and editors who were actively involved in the movement, including George Hecht, editor of Parents Magazine.

The drumbeat around the population crisis reached crescendo by the early 1960s. Readers of popular magazines were faced with a barrage of articles warning of an impending population crisis . . . Women readers were inundated with articles like “Are We Overworking the Stork?” (Parents Magazine, 1961), “Why Americans Must Limit Their Families” (Redbook, 1963), “Intelligent Woman’s Guide to the Population Explosion” (McCall’s, February 1965), “Overpopulation: Threat to Survival” (Parents Magazine, 1967) and “Population Increase: A Grave Threat to Every American Family” (Parents Magazine, 1969).

http://serbianna.com/blogs/savich/

Real Heroes Comics was published every other month from 1941 to 1946 in 16 issues from September, 1941 to October, 1946. George J. Hecht was the Publisher and Presiden

http://www.generalmihailovich.com/2011/04/draza-mihailovich-comic-book-hero.html

"Real Heroes" - 1942

"What Kind of Man is a Hero?" By George J. Hecht, President and Publisher
"Real Heroes" Comics and Founder of "Parents Magazine

http://www.faqs.org/childhood/Me-Pa/Parents-Magazine.html
...
The founder and publisher for over fifty years was George J. Hecht, a businessman and social service worker who had earned an economics degree from Cornell, then worked for Creel's Committee on Public Information during World War I.

[ The Creel Committee was a WWI Propaganda program !!!! ]

Hecht believed that even educated, middle-class parents needed access to knowledge and assistance in raising their children.  [ b.s. didn't give a rat's ass  he got paid by the Rockefeller's]

He received funding for his venture from the LAURA SPELMAN ROCKEFELLER MEMORIAL Foundation, a chief benefactor of the parent education movement.
 
Hecht recruited Clara Savage Littledale to serve as editor of the new magazine, a position she held for thirty years until her death in 1956. Littledale was a graduate of Smith College, a journalist, and the mother of two children. To make the latest findings in child development research available to parents, Littledale published articles on such topics as infant care, DISCIPLINE, character building, and SEX EDUCATION. Yet she was wary of parents relying too much on expert advice rather than their own common sense. She balanced research material with pieces based on humor, sentiment, and everyday experience, and included tips that readers sent in. She urged parents to relax and to enjoy their children–a message that presaged by at least a decade BENJAMIN SPOCK's Baby and Child Care.

http://www.ferris.edu/HTMLS/othersrv/isar/archives2/sources/bsh.htm
THE MENDEL NEWSLETTER
Archival Resources for the History of Genetics & Allied Sciences

SOURCES IN THE STUDY OF EUGENICS #2: THE BUREAU OF SOCIAL HYGIENE PAPERS
No. 16 (September 1978)

The Rockefeller Archive Center, located at the Rockefeller estate in Pocantico Hills, North Tarrytown, New York, contains five major collections of interest to, eugenics researchers
- the Bureau of Social Hygiene Papers, 1911-40 (78 boxes),
the Laura Spelman Rockefeller Memorial Fund Papers, 1918-41 (138 boxes),
the Rockefeller Foundation Archives, 1913-41 (over 500 boxes),
the Frederick Gates Papers, 1877-1939 (5 boxes), and the recently acquired
Population Council Papers.

These collections contain a good deal of material related to the development of the eugenics movement in the United States, including correspondence with such well known figures as Charles B. Davenport, C. C. Little, Henry Fairfield Osborn, Raymond Pearl and Irving Fisher.

The Bureau of Social Hygiene was a social science research institute concerned primarily with studies on the causes and control of crime. The range of topics covered by the Bureau in its thirty-year history includes prostitution, penal institutions, juvenile delinquency, criminal law, police systems and police training, ballistics and identification research, narcotics control, sex education, maternal health, birth control, venereal disease and population control. Many of these topics are distinctly eugenical in conception or impact. Among the Bureau Papers of interest to the historian of eugenics are files on eugenical sterilization in the U.S., the feebleminded and insane, the Third International Congress of Eugenics (1932), as well as manuscripts of numerous studies on the nature and causes of crime, vice, and drug addiction.

The Bureau of Social Hygiene grew out of the appointment of John D. Rockefeller, Jr. to a special grand jury investigation of the white slave trade in New York in 1910.

Rockefeller served as foreman for this investigation, which was scheduled to last for one mouth. He kept the investigation going for six months and in the end released a detailed report calling for a permanent commission to investigate "social evil… in the leading cities of this country and Europe…."(1) When the mayor refused to set up such a commission, JDR Jr. decided to do it himself. (2) He interviewed over a hundred educators, intellectuals and businessmen about the project. On March 22, 1911, the Committee of Three (JDR Jr., Paul Warburg and Starr Murphy) met and organized the Bureau of Social Hygiene. The name was first used in October 1911, although the organization was not formally incorporated until 1913.(3) Katherine B. Davis, former commissioner of Charities and Correction of New York and superintendent of the Bedford Hills Reformatory for Women, was chosen as the first general secretary.(4) The purpose of the Bureau was "the study, amelioration, and prevention of those social conditions, crimes, and diseases which adversely affect the well being of society…."(5)

...

http://en.wikipedia.org/wiki/International_Eugenics_Conference
...
The Third International Eugenics Congress (1932)
 
The third meeting was arranged at the American Museum of Natural History in New York City August 22–23, 1932, dedicated to Mary Williamson Averell who had provided significant financial support, and presided by Davenport. Osborn's address emphasized birth selection over birth control as the method to better the offspring.[6] F. Ramos from Cuba proposed that immigrants should be carefully checked for harmful traits, and suggested deportations of their descendants if inadmissible traits would become later apparent. Major Darwin, now 88 years old, was unable to attend but sent a report presented by Ronald Fisher predicting the doom of civilization unless eugenic measures were implemented.[7] Ernst Rüdin was unanimously elected president of the International Federation of Eugenics Societies.
 
Nazi implementation
 
After 1933 the Nazi government implemented eugenics according to the recommendations as made by Harry H. Laughlin and modified by Ernst Rüdin who wrote the 1933 Law for the Prevention of Hereditarily Diseased Offspring. In its propaganda the government could point to related steps in other European countries and the leadership that had been provided by the United States. Soon the process to rid society of "the unfit" was initiated.
 
No further International Eugenics Congresses were convened. [ no not really.... : ]

http://american_almanac.tripod.com/eugenics.htm
Eugenics and Population Control:
The 1935 Nazi World Population Conference, and the 1994 U.N. Cairo Population Conference --
More of the Same

by Gabriele Liebig

The Race Scientists
The International Congress for Population Science met from Aug. 26 to Sept. 1, 1935 at the Friedrich Wilhelm University. Sponsors were the German branch of the International Association for Population Science founded in Paris in 1928; the German Society for Racial Hygiene; and the German Statistical Society. At the second general assembly of the International Association for Population Science in 1931 in London, it had been resolved to hold the third general assembly in Berlin in 1934, according to the preface to the conference report.

Yet ``at the request of the executive committee'' it was postponed until 1935. ``Thereby German population science was offered the possibility ... for experts from every nation to examine the population laws it has devised and the government of the German Reich has put into force, as well as to examine the results of this scientifically based population policy, which are in part already manifest.''
Printed in The American Almanac, 1994.
...
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Rich people don't want any more poor people born....

Abby Rockefeller
Quote
http://www.popcouncil.org/pdfs/jadelle_monograph.pdf
...

Norplant capsule and Jadelle rod research and development were supported by several government agencies, foundations, and individuals:

the United States Agency for International Development (USAID) and
the International Development Research Centre of Canada;
the Ford Foundation,
the Andrew W. Mellon Foundation,
the Rockefeller Foundation,
the George F. Jewett Foundation,
the General Service Foundation,
and the estate/charitable trust of Abby Rockefeller Mauzé;
the United Nations Population Fund (UNFPA);
Mr. George J. Hecht (and, after his death, the George J. Hecht Fund) and
several members of the Rockefeller family;

http://en.wikipedia.org/wiki/Abby_Rockefeller_Mauz%C3%A9

Abby Rockefeller Mauzé

Unlike her famous brothers, she always remained out of the public eye. Among the many positions she held were: membership of the Board of Trustees of the Rockefeller Brothers Fund, set up by her and her brothers in 1940;
advisory member of the Board of Trustees of the Memorial Sloan-Kettering Cancer Center, (
a chief benefactor of the Center along with her brother, Laurance, she received its Medal of Appreciation in 1965); and honorary trustee of the Rockefeller Family Fund, founded by various family members in 1967.
 
She was also a benefactor of the Metropolitan Museum of Art, the YWCA, New York Hospital, the Museum of Modern Art (of which her mother was a founder, and in whose affairs her brothers Nelson and David played a major role); the New York Zoological Society (which was a major interest of her brother Laurance); and the Asia Society, which was established by another brother, John D. Rockefeller 3rd.
 
In 1968 Mrs. Mauzé created the Greenacre Foundation, of which she was president, in order to maintain and operate one or more parks in New York State for the benefit of the public. She also made cash and stock contributions to East Woods School, The Metropolitan Museum of Art, the Rockefeller Brothers Fund, New York Hospital,
the Population Council,
the Planned Parenthood Federation of America
, and
the American Red Cross.
 
She owned property in Bermuda, the Roman Corporation at One Beekman Place, and property at the Pocantico family estate (see Kykuit). She married three times (in 1925 to David M. Milton (1900–1976), a lawyer and had two daughters, Abby Rockefeller and Marilyn Rockefeller; in 1946 to Dr. Irving H. Pardee (1892–1949), without issue; and in 1953 to Jean Mauzé (1903–1974), without issue), and died on May 27, 1976, at her apartment in One Beekman Place in New York City.


...
http://en.wikipedia.org/wiki/Beekman_Place_(Manhattan)

...the luxurious sixteen-story co-op at 1 Beekman, built in 1930 by a syndicate headed by David M. Milton, the son-in-law of John D. Rockefeller Jr.
Milton's wife, Abby, was called by The New York Times 'the wealthiest young woman in America.'...

Early tenants at 1 Beekman included the diplomat David K. E. Bruce, William J. Donovan - who founded the Office of Strategic Services, the forerunner of the CIA - the Miltons, and John D. Rockefeller III."


Beekman Place is a small street located on the east side of Manhattan, New York City.
...
The British made their headquarters in the mansion for a time during the Revolutionary War and Nathan Hale was tried as a spy in the mansion's greenhouse and hanged in a nearby orchard. George Washington visited the house many times during his presidency.
...
One Beekman Place the 1929 co-op, designed by Sloan & Robertson and Corbett, Harrison & MacMurray, is "the most prestigious Beekman Place apartment building," according to Carter Horsley. It was built by a group headed by David Milton, husband of Abby Rockefeller and son-in-law of John D. Rockefeller, Jr. Early tenants here included "Wild Bill" Donovan of the OSS and John D. Rockefeller III and A&P Heir Huntington Hartford. Happy Rockefeller lived at One Beekman Place. It has a lavish tiled pool on the ground floor for the tenants and a basketball court and small ping pong table.

In the Movie Auntie Mame. Auntie Mame played by Rosalind Russell lives at Beekman Place. In the Movie Bonfire of the Vanities based on Tom Wolfe's book, the Mayor mentions Beekman Place. The Mayor in Bonfire of the Vanities says "They sit in their co-ops, Park Avenue, Fifth, Beekman Place, snug like a bug. Twelve-foot ceilings, a wing for them, one for the help".
...
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
So in 1973 they started the Manhattan Project of using vaccines for anti-fertility  . Five organizations with five different projects. Aimed at surpressing/ending Female and Male fertility


http://presscore.ca/2011/?p=1133

The deadly truth about genetically modified foods and vaccines – reproductive genocide.

The World Health Organization has a Task Force on the Regulation of Male Fertility. In 1990 a paper was published in Lancet, a well-regarded British medical journal detailing the use of testosterone injections to render men sterile. The abstract of the article noted “Hormonal regimens that induce azoospermia [lack of fertile sperm] can provide highly effective, sustained, and reversible male contraception with minimum side-effects.
 
http://www.ncbi.nlm.nih.gov/pubmed/1977002

...
The World Health Organization also has a Task Force on Vaccines for Fertility Regulation. An article in Human Reproduction (Human Reproduction, Vol. 6, No. 1, pp. 166-172, 1991© 1991 European Society of Human Reproduction and Embryology) called “The WHO Task Force on Vaccines for Fertility Regulation. Its formation, objectives and research activities” by P.D. Griffin of the Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization 1211 Geneva 27, Switzerland summarized its work this way:
 
“Over the past 18 years, the WHO Task Force on Vaccines for Fertility Regulation has been supporting basic and clinical research on the development of birth control vaccines directed against the gametes or the preimplantation embryo. These studies have involved the use of advanced procedures in peptide chemistry, hybridoma technology and molecular genetics as well as the evaluation of a number of novel approaches in general vaccinology. As a result of this international, collaborative effort, a prototype anti-HCG vaccine is now undergoing clinical testing, raising the prospect that a totally new family planning method may be available before the end of the current decade.”
 
That means that since 1973 the World Health Organization has been looking for ways to use vaccines and injections to control the world’s fertility. If those methods are offered to men and women so that they can make a choice about their reproductive lives, well and good. If, however, they are hidden in smallpox vaccines (Africa) with the avowed purpose of “eliminating 150 million excess Sub Saharan Africans” as they were in vaccines distributed by the WHO starting in 1985, or in tetanus vaccines which would cause abortions in South and Central America women starting in the 1990’s, we are not dealing with reproductive options, but reproductive genocide.
 
The FDA has approved the same sterility vaccine in the US . For what purpose? Which group will receive it in which vaccine, hidden in a syringe supposedly offered to “protect” patients?
 
Is the World Health Organization empowered to decide which group of people may reproduce and which must become sterile? And if so, by whom is it so empowered? How about the FDA?

| - - - -
Quote
In the early 1970s a group of scientists came together at the WHO to discuss the impact of the advances in biosciences on birth control

In 1973 the WHO established the Task Force on Vaccines for Fertility Regulation, as part of the HRP.

 http://whqlibdoc.who.int/publications/1988/9241561203_(chp11-12).pdf
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Your tax dollars at work USAID -  Notice they admit thier goal is to reduce TFT Total fertility Rates across the globe:



http://pdf.usaid.gov/pdf_docs/PDACF051.pdf
USAID From the American People
Report to Congress
Health-Related Research and Development Activities at USAID


USAID funds a wide range of research (including bio-medical, operations, social science, demographic, and policy-related research) and relevant technical assistance that has a direct effect on increasing contraceptive use, reducing total fertility rates,


http://www.finrrage.org/pdf_files/Contraception/Stop_Research_Anti_Fert_Vac.pdf
CALL FOR A STOP OF RESEARCH ON ANTIFERTILITY ‘VACCINES’
(immunological contraceptives)

We, the undersigned, call for an immediate halt to the development of immunological contraceptives
because of concerns about health risks, potential for abuse, unethical research, and the assumptions
underlying this direction of contraceptive research. ...


http://www.globalresearch.ca/index.php?context=va&aid=20906
Rockefeller-Funded Anti-Fertility Vaccine Coordinated by WHO
by Jurriaan Maessen
...

In 1976, the WHO Expanded Programme of Research, Development and Research Training in Human Reproduction published a report, stating:

“In 1972 the Organization (…) expanded its programme of research in human reproduction to provide an international focus for an intensified effort to improve existing methods of fertility regulation, to develop new methods and to assist national authorities in devising the best ways of providing them on a continuing basis. The programme is closely integrated with other WHO research on the delivery of family planning care by health services, which in turn feeds into WHO’s technical assistance programme to governments at the service level.”

Although the term “Anti-Fertility Vaccine”, coined by the Rockefeller Foundation, was replaced by the more bureaucratic sounding “Fertility Regulating Vaccine (FRV), the programme was obviously the same. Besides, The time line shows conclusively that the WHO, UN Population Fund and World Bank continued on a path outlined by the Rockefellers in the late 1960s. By extensions, it proves that all these organization are perfectly interlocked, best captured under the header “Scientific Dictatorship”. The relationship between the WHO and the Rockefeller Foundation is intense. While researching the effectiveness of “gossypol” as an “antifertility agent”, the bulletin states:

The Rockefeller Foundation has supported limited clinical trials in China and smallscale clinical studies in Brazil and Austria. The dose administered in the current Chinese trial has been reduced from 20 mg to 10-15 mg/day during the loading phase in order to see if severe oligospermia rather than consistent azoospermia would be adequate for an acceptable, non-toxic and reversible effect. Meanwhile, both the WHO human reproduction programme and the Rockefeller Foundation are supporting animal studies to better define the mechanism of action of gossypol.”
...
The picture emerging from these facts is clear. The WHO, as a global coordinating body, has since the early 70s continued the development of the Rockefeller-funded “anti-fertility vaccine”. What also is becoming clear, is that extensive research has been done to the delivery systems in which these anti-fertility components can be buried, such as regular anti-viral vaccines. It’s a mass-scale anti-fertilization programme with the aim of reducing the world’s population: a dream long cherished by the global elite.


Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
http://www.akha.org/content/vaccinations/talwar3.pdf
Human Reproduction Update 1997, Vol. 3, No. 4 pp. 301–310
G.P.Talwar
International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi-110067, India

Fertility regulating and immunotherapeutic vaccines reaching human trials stage

The progress and current status of vaccines which induce antibodies against human chorionic gonadotrophin (HCG) and luteinizing hormone-releasing hormone (LHRH) are reviewed. Three vaccines devised against HCG have undergone phase I clinical trials documenting their safety, and reversibility. One of these, the heterospecies dimer (HSD)–HCG vaccine has also completed  phase II efficacy trials in sexually active women of proven fertility. Immunization with the vaccine prevents pregnancy, as long as the antibody titres remain .50 ng/ml HCG bioneutralization capacity. There is no disturbance of menstrual regularity and women continue to ovulate normally. The antibody response is predominantly againsy an epitope in the core part of b-HCG. Fertility is regained at titres <35 ng.

These observations have laid the scientific foundations of a birth control vaccine. Research suggests the feasibility of making a cost-effective recombinant vaccine. The carriers tetanus toxoid (TT) and diptheria toxoid (DT) can be advantageously replaced by peptide determinants recognizing T, not B cells. In addition to optional fertility control, HCG vaccines may have tumour growth inhibition potential in lung cancers which produce HCG.

The vaccine against LHRH can be used in both males and females. As it is a structurally conserved molecule, the same vaccine is applicable to both animals and humans. Antibodies against LHRH block the generation of gametes and sex steroids, with the result that the vaccine can be used for fertility control (domestic pets, prolongation of lactation amenorrhoea); as well as for sex hormone-dependent cancers. Phase I/phase II  clinical trials have been conducted with the LHRH vaccine in advanced metastazing carcinoma of prostate patients with encouraging results. Bioeffective monoclonal antibodies have been developed against both LHRH and HCG. These can be ‘humanized’ and produced cost-effectively in bacteria and plants, thus paving the way for passive use of such antibodies for immunotherapy of cancers and fertility control.
...
Acknowledgements

The work on LHRH and HCG vaccines was supported by research grants of The Rockefeller Foundation, The International Development Research Centre (IDRC) of Canada, the Dept.of Biotechnology Govt. of India and The EC grant No. TS3*- CT94–0292.

http://www.factoverfiction.com/article/4984
Secret Sterilizing Ingredients In Many Vaccines (Article)
...
Fertility has been declining rapidly since the 1950s in all countries   of the world and the start of the change coincided with the   introduction of the first mass vaccination programs. For instance, in   the UK in 1947, a mass DPT vaccine campaign was initiated and in 1958,   the first polio and diphtheria vaccines were brought in on a mass scale   for all people under 15 years old.

Spermicide in Vaccines
...
Octoxynol 10 (Triton X-100) is contained in vaccines
...
Polysorbate 80 Causes Infertility
Another ingredient that is problematic is polysorbate 80 (also known   as tween 80) that is in numerous vaccines including the Pediacel   five-in-one vaccine given to infants and the gardasil HPV vaccine.   Polysorbate 80 is a known sterility causing agent in rats. It caused   changes to the vagina and womb, ovary deformities and degenerative   follicles and this impaired the rats’ ability to reproduce.

According to the World Intellectual Property Organization, which  is part of the United Nations, scientists from the organization are developing vaccines specifically to damage fertility as a method of contraception. A suggested ingredient for the vaccine  is Polysorbate 80 (also known as tween 80). As it is a preferred ingredient, scientists are obviously aware of its ability to cause infertility.

...
Gulf War Syndrome Victims Infertile

Squalene (shark liver oil) is used in the H1N1, HPV and anthrax  vaccines, as well as others, as an adjuvant to make the recipient  produce more antibodies and also to spread out the vaccine so they can make more of it for less money.

It has been implicated in the devastating immune dysfunctions of the soldiers who suffered from Gulf War Syndrome, many of whom returned from the Gulf with infertility problems.

Noreen Maconochie, Rebecca Simmons and colleagues at the London School of Hygiene and Tropical Medicine did   a postal survey and found that 2.5% of men who had been to the Gulf   failed to get their wives pregnant, compared 1.7% of men who hadn’t been   to the Gulf. In addition, there were another 3.4% whose wives had  miscarried. Soldiers in America were so worried about the military   vaccination programme making them infertile that they were freezing  their sperm before they had any vaccines.

Polysorbate 80 and Squalene Together are Ideal Sterilizing Agents
Far from being mere anecdotal reports, scientists are aware that an   ideal sterilizing recipe is polysorbate 80 and squalene oil together, as   they demonstrated in this patent for an animal contraceptive vaccine:

“In a preferred embodiment the vaccine comprises oil, preferably a biodegradable oil such as squalene oil. Typically, the vaccine is prepared using an adjuvant concentrate which contains lecithin in   squalene oil. The aqueous solution glycoprotein is typically a  phosphate-buffered saline (PBS) solution, and additionally preferably  contains Tween 80.”
...

So if you’re considering having a vaccine or giving your child one,   don’t have any if you intend to get pregnant within three months of the   vaccine and avoid any vaccines that contain polysorbate 80, octoxynol 10   (Triton X-100) or squalene (known as adjuvant AS04).

for Reference:
Vaccine overview: Basic information on M59 Squalene Vaccine Adjuvant ]
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
http://whqlibdoc.who.int/hq/1993/WHO_HRP_WHO_93.1.pdf
Fertility Regulating Vaccines - Aug 1992 - WHO Report

Notice a year or so later...... we have the Tetenus vaccine fiasco.... "Secret Vaccine Trials":

http://www.whale.to/vaccine/miscarriage_vax_h.html
...
Quotes - "At present, we are doing research on the Tetanus Vaccines that were given last March 1994 by our Dept. of Health to women of reproductive age.

Many of the women complained of bleeding (miscarriages) and allergies. We got alarmed recently when we received communications from Magally Llaguno that the vaccine in Mexico contained hCG . . . If you have enough [research] papers, could your group do a press release via international press like Reuters so that all countries could be alerted?" Genocide in a vaccine: Pantheism's moral Chemistry by Suzanne Rini

"In 1995, a Catholic human rights organization called Human Life International accused the WHO of promoting a Canadian-made tetanus vaccine laced with a pregancy hormone called human choriogonadotropic hormone (HCG).

Suspicions were aroused when the tetanus vaccine was prescribed in the unusual dose of five multiple injections over a three month period, and recommended only to women of reproductive age. When an unusual number of  women experienced vaginal bleeding and miscarriages after the shots, a  hormone additive was uncovered as the cause.

Apparently the WHO has been developing and testing anti-fertility vaccines  for over two decades.

Women receiving the laced tetanus shot not only developed antibodies to tetanus, but they also developed dangerous antibodies to the pregnancy hormone as well.

Without this HCG hormone the growth of the fetus is impaired. Consequently, the laced vaccine served as a covert contraceptive device. Commissioned to analyze the vaccine, the Philippines Medical Association  found that 20 percent of the WHO  tetanus vaccines were contaminated with the hormone.

Not surprisingly, the WHO has denied all accusations as "completely false and without basis," and the major media have never reported on  the controversy. For futher details on this issue, consult the Human Life International website (www.hli.org)."--- Dr Alan Cantwell MD

Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #10 on: January 16, 2012, 08:57:56 PM »
http://www.chidicon.com/files/UNICEF_Nigerian_Polio_Vaccine_Contaminated_with_Sterilizing_Agents_Scientist_Finds.doc
UNICEF Nigerian Polio Vaccine Contaminated with Sterilizing Agents Scientist Finds
Scientist says things discovered in vaccines are "harmful, toxic"
KADUNA, Nigeria, March 11, 2004 (LifeSiteNews.com) - A UNICEF campaign to vaccinate Nigeria's youth against polio may have been a front for sterilizing the nation. Dr. Haruna Kaita, a pharmaceutical scientist and Dean of the Faculty of Pharmaceutical Sciences of Ahmadu Bello University in Zaria, took samples of the vaccine to labs in India for analysis.

Using WHO-recommended technologies like Gas Chromatography (GC) and Radio-Immuno assay, Dr. Kaita, upon analysis, found evidence of serious contamination. "Some of the things we discovered in the vaccines are harmful, toxic; some have direct effects on the human reproductive system," he said in an interview with Kaduna's Weekly Trust. "I and some other professional colleagues who are Indians who were in the Lab could not believe the discovery," he said.

A Nigerian government doctor tried to persuade Dr. Kaita that the contaminants would have no bearing on human reproduction. "…I was surprised when one of the federal government doctors was telling me something contrary to what I have learned, studied, taught and is the common knowledge of all pharmaceutical scientists -- that estrogen cannot induce an anti-fertility response in humans," he said. "I found that argument very disturbing and ridiculous."
...
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #11 on: January 16, 2012, 10:04:17 PM »
http://nichd.nih.gov/publications/pubs/upload/CRHB-council-report-june-2008.pdf
EXECUTIVE SUMMARY

This document is the quadrennial report of the Contraception and Reproductive Health Branch (CRHB) to the National Advisory Child Health and Human Development (NACHHD) Council. The CRHB is a Branch within the Center for Population Research (CPR) at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The CRHB provides the NICHD with a focus for research and research training in contraception and other selected areas of reproductive health.

Between 2004 and 2007, the Branch supported activities in five program areas:

• Contraceptive Research and Development
• Contraceptive and Reproductive Evaluation
• Prevention of HIV/AIDS and Other Sexually Transmitted Diseases (STDs)
• Selected Reproductive and Other Gynecologic Health Issues
• Research Training

In the area of Contraceptive Research and Development, the Branch supports research through both grant and contract mechanisms. It maintains an investigator-initiated grant portfolio primarily focused on contraceptive research. In addition, the Branch provides support for four sites under the U54 Contraceptive Development Research Center Program (CDRCP) and eight sites under the U01 Male Contraceptive Development Program.

Three support contracts, including a biological testing facility, a chemical synthesis facility, and a peptide synthesis facility are also supported through the Branch. In addition, the CRHB supports a center for synthesis and testing of non-steroidal and non-hormonal male contraceptive agents. The Branch’s largest contract program is the Contraceptive Clinical Trials Network (CCTN), which includes 12 sites for female contraceptive research, two sites for male contraceptive research, and a data coordinating center.

...
The federal government has supported contraceptive research and development activities since 1968, when the Assistant Secretary for Health and Scientific Affairs of the then Department of Health, Education, and Welfare established the Center for Population Research (CPR) at the NICHD, with the goal of developing new contraceptives.

In 1970, congress passed Public Law 91-572, adding Title X to the Public Health Service Act to authorize grants and contracts for research and research training in family planning and population sciences.

Additional support came in 1993, when congress passed legislation (Public Law 103-43) directing the NICHD to establish extramural centers devoted to contraceptive research and development.

This goal was re-emphasized in the 1996 amendment to the Public Health Service Act.
...
SpermCheck
Researchers identified a sperm-specific antigen as a potential target for the development of a contraceptive vaccine, but proof-of-efficacy studies in animals were not successful. However, this highly specific antigen formed the basis of a different product, which measures sperm concentration in semen. The product recently launched commercially and will be a useful adjunct in determining efficacy of hormonal, non-hormonal, or surgical contraception in men.

http://www.conrad.org/contraception-grid.html


NOVEL FEMALE LEADS – The objective of this activity is to identify target molecules that have potential as leads for novel non-hormonal, non-barrier female contraceptives.

 Inhibitory peptides are being developed against three targets and their half-life extended by PEGylation. THE GnRH II receptor, which predominates in reproductive tissue, is under investigation as an additional target.

 Synthesis and anti-fertility testing of inhibitory peptides by vaginal application in mice has been completed. Of the three targets being investigated using PEGylated inhibitors, inhibition of one target molecule did not adequately inhibit pregnancy, but inhibition of the other two appears promising and will be further pursued within funding limitations.
 
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #12 on: January 17, 2012, 01:42:31 PM »
http://www.finrrage.org/pdf_files/Conference%20Reports/ImmunologicalContraceptives.pdf

Workshop on Immunological Contraceptives (Antifertility ‘Vaccines’), 7th International Women
and Health Meeting, Kampala,Uganda, 12-l8th September 1993
CLINICAL TRIALS OF IMMUNOLOGICAL CONTRACEPTIVES -Judith Richter

Funding:
Pop. Council’s “programmatic funds”
(i.e. George J.Hecht Fund: ]The Andrew W.Mellon Foundation: The Rockefeller Foundation).
- Anti-sperm contraceptives - mainly for women (CONRAD, NICHD. NII, Pop. Council).
John Herr, Virginia University, planning human trials in 1995 depending on outcome
animal trials (funding: CONRAD)
- Anti-egg immune contraceptive (CONRAD, NII)
- Anti-trophoblast contraceptive (WHP/HRP)

http://www.healthsystem.virginia.edu/internet/crcrh/people/jch7k.cfm
 Center for Research in Contraceptive & Reproductive Health

John C. Herr
Center Director;
Professor Cell Biology
CRCRH,
Department of Cell Biology
University of Virginia
Health System Box 800732
Charlottesville, VA 22908



Research
Our laboratory is focused on the structural characterization of sperm proteins and their encoding genes. Two fundamental concepts underlie this work. First, during spermatogenesis, the expression of genes unique to the spermatogenic lineage, results in sperm-specific polypeptides being incorporated into the sperm's cyto architecture. Such testis-specific genes provide good models for understanding the regulation of gene expression during the differentiation of spermatids into mature sperm. Second, the sequestration of sperm from the immune system by the blood-testis barrier allows for many sperm antigens to be recognized immunologically as autoantigens.

[ gene specific anti-sperm weapons - ie race based bio weapons ]

http://www.nap.edu/openbook.php?record_id=5156&page=401
C: Immunocontraceptive Approaches
John Christian Herr, Ph.D.

Department of Cell Biology and The Center for Recombinant Gamete Contraceptive Vaccinogens, University of Virginia

The purpose of an antifertility immunogen is to prevent fertility or early pregnancy. Traditional immunization against micro-organisms may often be the only means available for controlling a given disease; in the case of contraception, alternative methods are already available
...
The pathway for development of an immunocontraceptive follows a series of steps not unlike those followed in traditional vaccine development. These include: (1) fundamental discovery and characterization of appropriate immunogens derived from reproductive hormones and/or from the sperm, egg, egg investments, conceptus, or accessory reproductive organs; (2) development of methods for producing the immunogens to high standards of purity through (a) genetic engineering of genes encoding specific immunogens, (b) peptide syntheses, or (c) isolation of the antigen from natural sources; (3) production and purification of immunogens under good laboratory practices (GLP); (4) formulation of immunogen doses; (5) small animal and primate testing of immunogen formulations for immunogenicity, safety, and efficacy; (6) evaluation of mechanisms of immunogen action; (7) human trials for immunogenicity, safety, and efficacy, using formulations produced under good manufacturing practices (GMP); and (8) development of diagnostics to monitor infertility status in recipients of effective immunogens.


...
For purposes of simplification, mammalian reproduction may be divided into several key stages, each of which may offer an opportunity for intervention: (1) gamete production (spermatogenesis and oogenesis); (2) gamete shedding and transport (copulation; sperm transport in the cervix, uterus, and oviduct; ovulation and oviductal transport of the cumulus mass); (3) gamete interaction (capacitation, the acrosome reaction, penetration of the egg investments, fusion with the oolemma); (4) blastocyst transport and hatching; and (5) implantation. All of these events can theoretically be inhibited by eliciting an immune response directed against functionally and structurally important molecules that are accessible to immune effectors (antibody or cell mediated).
...

Synthetic Capability. Capacity to synthesize the immunogens in large quantities under good laboratory and good manufacturing practices is an important practical requirement for selecting molecules for clinical testing. Use of the natural tissues as starting materials for immunocontraceptive production is possible; however, isolation processes from natural sources are much more difficult to control from the standpoint of safety than are standard synthetic or genetic engineering procedures.
.... [ read more of this ... ]


http://www.slideshare.net/many87/clinical-trials-of-immunological-contraceptives
CLINICAL TRIALS OF IMMUNOLOGICAL CONTRACEPTIVES — Document Transcript

 1. Workshop on Immunological Contraceptives (Antifertility ‘Vaccines’), 7th International Women and Health Meeting, Kampala,Uganda, 12-l8th September 1993 CLINICAL TRIALS OF IMMUNOLOGICAL CONTRACEPTIVES Judith Richter

Organisation of the background paper:

1. The five major research coordination centres
2. Maps on clinical trials by coordinating centre (WHO. NII. Pop. Council)
3. Pre-clinical research (& map of additional research teams)
 I. THE FIVE MAJOR RESEARCH COORDINATING CENTRES The World Health Organization. Special Programme of Research. DeveloDment and Research Training in Human Reproduction (WHO/HRP).

Geneva: Coordinator: David Griffin. Manager of the Task Force on Fertility Regulating Vaccines The National Institute of Immunology (NII).
New Delhi: Coordinator: G.Pran Talwar. Professor of Eminence and former director of the Institute The Population Council. New York: Coordinator: Rosemary Than, Director of Contraceptive Research The Contraceptive Development Programme (CONRAD).
 East Virginia Medical School, in Norfolk, Virginia. U.S.A. Coordinator: Henry Gabelnick, Program Director? The National Institute for Child Health and Development/National Institutes of Health (NICHD/NIH), Bethesda, Maryland, U.S.A. Coordinator: Gabriel Bialy. Chief of the Contraceptive Development Branch of the Centre for Population Research?

2. II. MAPS ON CLINICAL TRIALS THE WORLD HEALTH ORGANIZATION WHO/HRP Clinical trials:

Prototype anti-hCG contraceptive (beta-hCG-CTP): −
 
Phase I completed in 1988: 30 women: Flinders Medical Center, Adelaide, Australia (Warren R. Jones) −

Phase II planned for 1993: **) About 200 women: Karolinska Institute, Stockholm, Sweden (S.Cekan?) & University Hospital, Uppsala, Sweden (V.Odlind?). NB:

Formulation of product by a Swedish company (G.Thorell, Galenus, Uppsala?) Advanced prototype (i.e. microcapsule formulation): −
Phase I: planned for 1994/5 (in same Swedish Institutes) Funding: General HRP funding, i.e. UNDP: UNFPA: World Bank: governments of Denmark, Norway, Sweden. UK, Germany etc.

Phase I of prototype: moreover Sandoz Phase II: moreover Swedish government (liability coverage) **) update April ‘94: about 50 women / the first ones were ‘Vaccinated’ just recently

3. THE NATIONAL INSTITUTE OF IMMUNOLOGY NII Prototype anti-hCG contraceptive: -

Phase I completed in 1990 (several hCG formulations): 101 women in 5 Indian centres -

Phase II completed in 1993 (alpha-oLH:beta-hCG): Originally planned 180 women, stopped at around 105 women: All India Institute of Medical Sciences (AIIMS), New Delhi (K. Buckshee: L. Saraya): Safdarjung Hospital, New Delhi (S.K.Das: S.Suri): Postgraduate Institute of Medical Education and Research, Chandigarh (PGI) (K. Dhall: A.Sarkar). -

Phase III Planned (potentially combined with “phase I/II” trial of intrauterine neem extract administration - Praneem VILCI - for the lag-phase of.immunological contraceptives). Funding (of phase I & II trials): Government of India (Science and Technology Project of the Department of Biotechnology):
The International Development Research Centre (IDRC) of Canada: The Rockefeller Foundation Anti-GnRH contraceptive (“to prolong lactational amenorrhoea”): -

Phase I in 1992?: At least 20 women, Safdarjung Hospital?: University College of Medical Sciences, both New Delhi, India Funding: South to South Cooperation in Reproductive Health. Salvador, Bahia, Brazil (Rockefeller funded): others? Anti-GnRH auto-immunization against protstate cancer: - Phase I: ? men. 2 centres in India. 1 in Austria (J. Frick), 1 in Mexico? Funding: N.D.

4. THE POPULATION COUNCIL Anti-hCG immune contraceptive (beta-hCG): -

Phase I study completed in 1991: 24 women: Instituto Chileno de Medicina Reproductiva, Santiago, Chile (H.Croxatto): University of Helsinki, Finland (T.Luukainen): Association Dominicana Pro Bienestar de la Familia, Santo Domingo, Dominican Republic (F.Alvarez: V.Brache) -

Currently no phase II planned Funding: Pop. Council’s “programmatic funds” (i.e. Georg J.Hecht Fund: The Andrew W.Mellon Foundation: The Rockefeller Foundation).

Anti-GnRH auto-immunization against prostate cancer: -

“Phase I”, 4 (potentially 10 more) men with prostate cancer, unknown trial centre in USA. NB: If no major adverse effects, plan to test anti-GnRH formula as male contraceptive for healthy men Funding: NIH, programmatic funds, USAID, Dodge Foundation Anti-FSH (oFSH): - Phase I planned, trial centres unknown (USA?) Funding: USAID?

5. III. PRE-CLINICAL RESEARCH Before mentioned five organisations are moreover doing laboratory and/or animal studies on: - Anti-GnRH contraceptive, clinical trial planned by NICHD - Anti-sperm contraceptives - mainly for women (CONRAD, NICHD. NII, Pop. Council).

John Herr, Virginia University, planning human trials in 1995 depending on outcome animal trials (funding: CONRAD) - Anti-egg immune contraceptive (CONRAD, NII) - Anti-trophoblast contraceptive (WHP/HRP) Other research teams (*) include: - Dominioue Bellet. Institut Gustave-Roussy, France.

Focus: anti-hCG contraceptive. Planning clinical trials? - M.R Moudgal, Indian Institute of Science, Bangalore, India.

Focus: anti-FSH contraceptives in men (potentially already phase I trials (funding: CONRAD: Indian government?) - John Aitken, Reproductive Biology Unit of Edinburgh University, UK; Jacques Testard, Institut National de la Sante et de la Recherche Medicale (INSERM), France, Focus: anti-egg contraceptives. - Mohamed A.Isahakia & Charanjit S.Bambra, Institute of Primate Research, National Museums of Kenya, Nairobi.

Focus: anti-sperm and anti-egg contraceptives .(funding: CONRAD). - Peter M. Johnson, Department of Immunology, University of Liverpool, UK; C.S. Bambra, National Museums of Kenya, Nairobi (funding: e.g. WHO/HRP): ? & ?, Hamburg, Germany. Focus: anti-trophoblast contraceptives.

Note:

Earlier clinical trials by the Population Council and the National Institute of Immunology (often referred to as “probing clinical trials”) have been left out of this survey. It is difficult to get complete (and consistent) data on some of the clinical trials. The survey should therefore be seen as provisional.


| - - - -

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481230/
Immunogenicity of a multi-component recombinant human acrosomal protein vaccine in female Macaca fascicularis

Barbara E. Kurth,a1 Laura Digilio,a1 Phillip Snow,a1 Leigh Ann Bush,a1 Michael Wolkowicz,a1 Jagathpala Shetty,a1 Arabinda Mandal,a1 Zhonglin Hao,b P. Prabhakara Reddi,a2 Charles J. Flickinger,a1 and John C. Herr a1*

A vaccine formula comprised of five recombinant human intra-acrosomal sperm proteins was innoculated into female monkeys to test whether specific antibodies to each component immunogen could be elicited in sera and whether antibodies elicited by the vaccine affected in vitro fertilization.

 
Immunization of females with sperm-specific antigens has been considered the basis of a new means of contraception. In practice, however, the development of a contraceptive vaccine for use by women has been hampered by two issues. First, no single germ cell-specific antigen has yet proven to have sufficient efficacy in vivo in non-human primates to warrant a human trial (Thau and Sundaram, 1980; Goldberg et al., 1981; O'Hern et al., 1995, 1997; Paterson et al., 1999). Second, many adjuvants that might increase the immunogenicity of molecules are not yet approved for use in humans (Thau and Sundaram, 1980; Goldberg et al., 1981; Jones et al., 1988; Talwar et al., 1990; Griffin, 1994; O'Hern et al., 1995, 1997; Stevens, 1996; Paterson et al., 1999).

...
The scarcity of adjuvants approved for use in the human population has severely restricted options for the formulation of a contraceptive vaccine.

Normally in a laboratory setting, animals are administered antigens using adjuvants that will maximize the amount of antibody produced. Some of those adjuvants are oil/water emulsions, such as Freund’s complete and incomplete adjuvant, immunostimulatory substances like muramyl dipeptide derivatives, saponins, monophosphoryl Lipid A, cytokines, CpG oligos, diphtheria toxoid, tetanus toxoid, cholera toxin or combinations of these.

Liposomes and polymer microspheres have been used with increasing frequency in the hopes of developing alternative routes (intranasal) of administration of vaccines.

However, adverse events can be associated with vaccine adjuvants, including injection site granulomas, abscesses, arthritis, amyloidosis, allergic reactions, systemic toxicity and pyrogenicity (Gupta et al., 1993; Macy, 1997; Singh and O'Hagan, 1999; Scheibner, 2000).

Thus, in contrast to the array of adjuvants available for laboratory use, safety considerations have so far limited universally approved adjuvants for vaccines intended for human use to aluminum compounds.

Therefore, to obtain preclinical data, this study was conducted in a primate model using a multicomponent vaccine consisting of human recombinant acrosomal proteins adsorbed to aluminum hydroxide.

Specific aims of the study were:
1) to determine whether sperm antigens, when administered as a mixture, were immunogenic in cynomolgus monkeys;
2) to determine whether serum antibodies raised to the recombinant proteins also reacted with the endogenous sperm proteins;
3) to determine whether IgG and IgA antibodies would be elicited;
4) to determine the approximate duration of the antibody response, and
5) to determine whether serum from immunized monkeys had an effect on sperm-egg interaction in vitro.
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #13 on: January 17, 2012, 04:26:20 PM »
Quote
http://en.wikipedia.org/wiki/Freund's_adjuvant

Freund's adjuvant is a solution of antigen emulsified in mineral oil and used as an immunopotentiator (booster).

The complete form, Freund's Complete Adjuvant,(CFA or FCA) is composed of inactivated and dried mycobacteria (usually M. tuberculosis), whereas the incomplete form (IFA or FIA) lacks the mycobacterial components (hence just the water in oil emulsion). It is named after Jules T. Freund.
...
Its use in humans is forbidden by regulatory authorities, due to its toxicity. Even for animal research there are currently guidelines associated with its use, due to its painful reaction and potential for tissue damage. Injections of CFA should be subcutaneous or intraperitoneal, because intradermal injections may cause skin ulceration and necrosis; intramuscular injections may lead to temporary or permanent muscle lesion, and intravenous injections may produce pulmonary lipid embolism

http://en.wikipedia.org/wiki/Mycobacterium_tuberculosis

Mycobacterium tuberculosis (MTB) is a pathogenic bacterial species in the genus Mycobacterium and the causative agent of most cases of tuberculosis (TB). ... The M. tuberculosis genome was sequenced in 1998 [ i.e. it can be re-engineered for hyper virulence! ]

Hypervirulent strains
 
Mycobacterium outbreaks are often caused by hypervirulent strains of M. tuberculosis. In laboratory experiments, these clinical isolates elicit unusual immunopathology, and may be either hyperinflammatory or hypoinflammatory. Studies have shown the majority of hypervirulent mutants have deletions in their cell wall-modifying enzymes or regulators that respond to environmental stimuli. Studies of these mutants have indicated the mechanisms that enable M. tuberculosis to mask its full pathogenic potential, inducing a granuloma that provides a protective niche, and enable the bacilli to sustain a long-term, persistent infection

http://www.wisegeek.com/what-is-freunds-complete-adjuvant.htm ...
. This kind is a water-in-oil emulsion, localizes antigens for release for about 6 months.
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #14 on: January 18, 2012, 02:00:21 PM »
Added Immunocontraception  "Anti-fertiliy" vaccine development to :

Global Eugenics Pandemic Timeline

1926 - George J. Hecht begins publishing Parents magazine with funding from the LAURA SPELMAN ROCKEFELLER MEMORIAL Foundation

1960's - Researchers realised that some forms of infertility can be caused by the action of the immune response in women or men against sperm

1969 - Nixon ends BioWarfare development with Geneva Accord

1969 - Nixon signs Title X - Commission on Population Growth and the American Future - Special Message to the Congress on Problems of Population Growth," presented on July 18, 1969


1970's - The first clinical trials with anti-fertility vaccines began in the 1970s

1971 - Nixon begins "War on Cancer" Rockefeller Plans
1972 - 69 acres of Fort Detrick's Area A were transferred to the NCI, to create the Frederick Cancer Research Facility

1972 - Chairman John D. Rockefeller - Commission on Population Growth and the American Future - the Final Report, containing the findings and recommendations, of the Commission on Population Growth and the American Future

1973 - 1973 the WHO established the Task Force on Vaccines for Fertility Regulation, as part of the HRP


1993 - Workshop on Immunological Contraceptives (Antifertility ‘Vaccines’), 7th International Women and Health Meeting, Kampala,Uganda, 12-l8th September 1993
Funding: Population Council’s “programmatic funds”  (i.e. George J.Hecht Fund : The Andrew W.Mellon Foundation : The Rockefeller Foundation).


1995 - Currently five large and a number of small institutions are conducting research on anti-fertility vaccines. WHO/HRP, Switzerland. The Population Council, United States, National Institute of Immunology, India, The Contraceptive Development Program (CONRAD), United States, The Center for Population Research at the National Institute of Child Health and Development/the National Institutes of Health (NICHD/NIH), United States

2000 - Young Danes' sperm count dips - It found that 43% of them had sperm counts low enough to lead to decreased fertility

2002 July - First synthetic virus created - Synthetic Polio (First Documented) - Battelle - Synthetic Biology
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #15 on: January 18, 2012, 02:31:30 PM »
http://www.akha.org/content/vaccinations/talwar3.pdf
Human Reproduction Update 1997, Vol. 3, No. 4 pp. 301–310  European Society for Human Reproduction and Embryology

Fertility regulating and immunotherapeutic vaccines reaching human trials stage
G.P.Talwar
International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi-110067, India

Introduction
Research into birth control vaccines began with the conviction that the currently available contraceptive
methods do not suit all those seeking family planning.

 Fertility regulating vaccine(s), if feasible, would meet with the perceived requirements of: (i) reversibility; (ii) periodic intake; (iii) freedom from the risk of user failure; (iv) impairment of menstrual regularity or increased bleeding; and (v) no blockade of ovulation or normal production of sex hormones by the woman. The use of these vaccines would avoid the pharmacological intake of synthetic steroids and would, hopefully, be admissible at all stages of reproductive life, whether nulliparous [where intra-uterine devices (IUDs) are contra-indicated] or for women aged >30 years (especially in the case of smokers, where contraceptive steroids entail a significantly higher risk of cancer). These requirements are fulfilled by vaccines raised against human chorionic gonadotrophin (HCG). The possibility of causing a fertility block by
immunization with different antigens became evident in experimental animals by a variety of studies. Clinical reports
had also discussed infertility in humans ascribable to immunological factors. However, little was known about
how these individuals developed an immunological block, nor how it could be reversed reliably. Experimental
approaches to the production of birth control vaccines for the deliberate blocking of fertility had to ensure that reversibility
was not compromised; today, immuno-contraception is an active field of research.

There are 27 vaccines for regulating fertility under development (Talwar, 1997).

Six of these, all directed against reproductive tract hormones, have undergone Phase I clinical trials (see Table I) and one, the HSD–HCG vaccine, has also completed successfully Phase II efficacy studies (Talwar et al., 1994), providing evidence for the feasibility of safe, reversible and effective vaccination for control of fertility.

Three of the seven vaccines are targeted against HCG, two against luteinizing hormonereleasing hormone (LHRH) and one against follicle stimulating hormone (FSH). Moudgal et al.(1997) discuss FSH in this issue.

This article will, therefore, be restricted to a review of the current status of the vaccines against HCG
and LHRH/gonadotrophin-releasing hormone (GnRH).


An additional application of these vaccines is in cases of hormone-dependent cancers, e.g. carcinoma of the prostate (LHRH vaccine) and lung cancers which synthesize HCG (HCG vaccine).
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #16 on: January 18, 2012, 03:52:04 PM »
Search:  FRV Fertility regulating vaccine
a couple of articles:


http://thelineinthesand.net/2011/01/07/%E2%80%9Cmass-scale%E2%80%9D-fertility-reduction-developed-by-the-rockefeller-foundation-no-babies-for-you/
“Mass-Scale” Fertility Reduction Developed by the Rockefeller Foundation (No Babies for You!)
and

http://prevab.webs.com/thevaccine.htm
The Fertility Regulating Vaccine

Oh and notice 1990-20 = 1970 is the first anniversary??? what happened in 1970 exactly? :
Reproductive Health: a Key to a Brighter Future: Special 20th Anniversary Issue:
Special Programme of Research, Development and Research Training in Human Reproduction Biennial Report 1990-1991
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #17 on: January 23, 2012, 04:32:52 PM »
http://www.erasmusmc.nl/corp_home/corp_news-center/2012/2012-01/genen.menopauze.ontdekt/?lang=en
Jan 2012
New genes found indicating menopause

A group of researchers led by Erasmus MC has unraveled part of the secret behind the fertile period in women. They have found differences in the DNA that affect the point at which women go into menopausal transition.

Differences
Part of these differences can be found in genes associated with immunological processes which can play a role in extremely early menopausal transitions. The scientists describe their breakthrough in the leading scientific journal Nature Genetics.

At risk
Dr. Lisette Stolk, researcher at the Internal Medicine department, is the first author of the publication. Stolk: “A greater understanding of the start of menopause will later enable us to better determine whether someone is at risk for of all sorts of age-related diseases.  It can also, in the long-term, help us determine how {to create} we can help women suffering from early infertility.”

Population studies
The researchers, from Erasmus MC, UMC Groningen and VUmc, together with groups from other parts of the world (England, Italy, Estonia, the USA, Australia), made use of several population studies, including a longitudinal population study carried out among people living in Rotterdam, the so-called ERGO study of Erasmus MC. They examined a total of 50,000 women to find out which parts of DNA (the so-called SNPs) play a role in determining the age at which the menopause starts.

Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #18 on: February 27, 2012, 05:13:06 PM »
From Drudge:
Another step towards The "Brave New World"


http://www.nytimes.com/2012/02/27/health/research/scientists-use-stem-cells-to-generate-human-eggs.html?_r=1&hp
Scientists Use Stem Cells to Generate Human Eggs
By NICHOLAS WADE
Published: February 26, 2012

Researchers at Massachusetts General Hospital say they have extracted stem cells from human ovaries and made them generate egg cells.
...
The new research, by a team led by the biologist Jonathan L. Tilly, depends on a special protein found to mark the surface of reproductive cells like eggs and sperm. Using a cell-sorting machine that can separate out the marked cells, the team obtained reproductive cells from mouse ovaries and showed that the cells would generate viable egg cells that could be fertilized and produce embryos.

They then applied the same method to human ovaries donated by women at the Saitama Medical Center in Japan who were undergoing sex reassignment because of a gender identity disorder. As with the mice, the team was able to retrieve reproductive cells that produced immature egg cells when grown in the laboratory.
...
The results were published online Sunday by the journal Nature Medicine
...
the immediate use of the cells in question would be to generate egg cells for research use, like testing the effects of drugs ...cells grown in the laboratory often develop abnormalities, a problem that would need correction before any egg could be accepted for fertilization
[they know this because it's already been done in secret labs in China.... ]
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline Ambriel

  • Member
  • *****
  • Posts: 1,683
  • Dare to resist
    • Consfearacynewz
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #19 on: February 27, 2012, 06:25:41 PM »
Children of Men
http://www.imdb.com/title/tt0206634/
Plot

In 2027 worldwide female infertility has led to the collapse of society. The United Kingdom, the last known stable nation, is deluged by asylum seekers. In response, it has become a militarised police state as British forces round up and detain immigrants. Kidnapped by an immigrants rights group known as "The Fishes," former activist turned cynical bureaucrat Theo Faron (Clive Owen) is brought to its leader, his estranged wife Julian Taylor (Julianne Moore). The couple parted ways after their son died from a flu pandemic in 2008. Julian offers Theo money to acquire transit papers for a young female refugee named Kee (Clare-Hope Ashitey), which Theo obtains from his cousin Nigel (Danny Huston), a government minister. However, the papers require the bearer to be accompanied, so Theo agrees to escort Kee in exchange for more money. Luke (Chiwetel Ejiofor), a Fishes member, drives Theo, Kee, Julian and Miriam (Pam Ferris), a former midwife, towards the coast to a boat. They are ambushed by an armed gang and Julian is fatally shot. Two police officers stop their car, but Luke kills them and the group escapes to a safe house.

Kee reveals to Theo that she is pregnant, and that Julian told her that she should trust only him. Julian had intended to hand Kee over to the "Human Project", a group of scientists dedicated to curing infertility, supposedly based in the Azores. However, Luke proposes keeping Kee in England and she agrees to stay. That night, Theo awakens and eavesdrops on a meeting of Luke and other members. He discovers that Julian's death was orchestrated by the Fishes so they could use the baby as a political tool to support the coming revolution. Theo wakes Kee and Miriam and they steal a car, escaping to the secluded hideaway of aging hippie Jasper Palmer (Michael Caine), a former political cartoonist and Theo's friend. A plan is formulated to board the Human Project ship Tomorrow which will arrive offshore from the Bexhill refugee camp. Jasper proposes getting Syd (Peter Mullan), a camp guard, to smuggle them in. The Fishes trail the group to Jasper's hideout, but Theo, Miriam and Kee get away. Jasper stays behind to buy them some time. Before the Fishes arrive, he gives the government-issued suicide drug Quietus to his catatonic wife. A horrified Theo witnesses the Fishes gun him down before escaping with Miriam and Kee. Later, they meet Syd, who transports them to Bexhill as prisoners. When Kee begins having contractions on a bus, Miriam distracts a suspicious guard with mania and is taken away.

At the camp Theo and Kee meet Marichka (Oana Pellea), who provides a room where Kee gives birth to a girl. The next day, Syd locates Theo and Kee and informs them that a full-scale war between the army and the refugees including the Fishes, has begun. After seeing the baby Syd threatens to turn them in but they attack him and escape. Amidst the violent clash between refugees and British troops, the Fishes capture Kee. Theo tracks Kee and her baby to an apartment building which is under heavy fire from the military and escorts her out. Awed by the presence of a baby, the combatants stop fighting momentarily, enabling them to escape. Marichka leads them to a boat in a sewer, but refuses to join them. As Theo rows away, he reveals to Kee that he was shot. They then witness a full-scale aerial bombing of Bexhill by the Royal Air Force and Kee tells Theo she will name her baby Dylan after Theo's dead son. Theo loses consciousness and Kee begins to sing a lullaby, as the Tomorrow approaches through a fog.

Offline chris jones

  • Member
  • *****
  • Posts: 21,651
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #20 on: February 27, 2012, 06:29:26 PM »
 Hi T, brother you did your homework on that one, *bumped, good on ya. Crystal clear, population reduction, one of their many methods.
 What allways gets to me is how the elites see us, exactly what are we to them, its as if they live on a different planet, or are they are spiritualy and mentaly diseased.
 then it hits me, after my pondering on what their lives are like and having been employed by one, we are considered under a par of their   pet dog. I worked for a wealthy guy long ago, his breakfast was brought to him, he was clothed by a manservant, his personell attendent was on call 24/7, butlers maids, drivers, private doctor, etc.. the whole enchilada. They are in a seperate reality to say the FK least.
  His slave force basically kissed his arse, I didn't therfor it was a short employment.

Offline John_Back_From_The_Club_O

  • Member
  • *****
  • Posts: 9,166
    • From Hell to Veins
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #21 on: February 27, 2012, 09:58:47 PM »

Couldn't resist. ;D
The Crowd Shouted... “Give us Barabbas!” ... and People, The NWO Gave Him To You.
http://www.dominicanajournal.org/give-us-barabbas/

https://www.greatagain.gov

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
http://trenchpress.com/?p=39708
Young woman’s ovaries destroyed by Gardasil: Merck ‘forgot to research’ effects of vaccine on female reproduction

By admin


A newly-published study has revealed that Merck & Co., the corporate mastermind behind the infamous Gardasil vaccine for human papillomavirus (HPV), conveniently forgot to research the effects of this deadly vaccine on women’s reproductive systems.

http://www.naturalnews.com/041512_Gardasil_ovary_destruction_HPV_vaccine.html

And at least one young woman, in this case from Australia, bore the brunt of this inexcusable failure after discovering that her own ovaries had been completely destroyed as a result of getting the vaccine.

Published in the peer-reviewed British Medical Journal (BMJ), the harrowing recount of this young 16-year-old girl's experience should give pause to all parents currently being pressured by their doctors into having their young daughters jabbed with Gardasil. Robbed of her natural ability to experience full womanhood, this young woman experienced early menopause, in which her ovaries completely shut down before they were even able to fully develop.

Entitled Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination, this latest case study provides solid evidence that Gardasil is, at the very least, a serious threat to normal ovarian function. Not only was the damaged girl examined and verified to have had healthy ovaries prior to the shots, but there were no other identified factors besides Gardasil that could have possibly been involved in her sudden ill-fate.
...

Merck either intentionally or accidentally -- either option is completely unacceptable, by the way -- failed to check whether or not Gardasil has the potential to damage young women's reproductive systems, even though young women have always been the primary target market for the vaccine.
,...
As reported by investigative journalist Heidi Stevenson, there are at least two additive ingredients in Gardasil that may be responsible for damaging women's ovaries. These ingredients are polysorbate 80, an emulsifying preservative, and L-histidine, a natural amino acid. Both of these ingredients are, of course, used in processed foods, which millions of people consume every day. But injecting them into the body has a much different biological effect than simply consuming them.

As it turns out, polysorbate 80, which also goes by the names Tween 80, Alkest, and Canarcel, has been shown in studies to damage female reproduction. Not only does this chemical additive greatly accelerate sexual maturation in women, but it also tends to reduce the weight and function of both the ovaries and the uterus. Similarly, L-histidine, when injected into muscle tissue, can cause the body to develop an autoimmune response to the natural substance, which can lead to many of the serious side effects being observed in many young girls who have been jabbed with Gardasil
...


Learn more: http://www.naturalnews.com/041512_Gardasil_ovary_destruction_HPV_vaccine.html#ixzz2bCstTC00
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

worcesteradam

  • Guest
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #23 on: October 17, 2013, 09:47:24 AM »
This is all quite shocking

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #24 on: October 17, 2013, 01:06:26 PM »
This is all quite shocking

Absolutely - this is the NUMBER ONE research program in the WORLD ... your tax dollars at work...

http://www.nichd.nih.gov/research/supported/Pages/biotest.aspx
Biological Testing Facility

The Biological Testing Facility, funded under contract with the Contraception Discovery and Development Branch (CDDB) (formerly the Contraception and Reproductive Health (CRH) Branch). undertakes more than 150 screens, assays, safety tests, and analytical procedures for the evaluation of new drugs, formulations, and delivery systems for compounds of interest for contraception and reproductive health research.

The Facility screens submissions of drugs for classical endocrine and anti-fertility activity and establishes potency ratios for those that exhibit significant effects. It has also developed methods for determining the duration of hormonal activity following oral, subcutaneous, or transdermal administration.


http://www.nichd.nih.gov/about/org/der/branches/cddb/Pages/overview.aspx
Contraceptive Discovery and Development Branch (CDDB)

Overview
The CDDB, formerly the Contraception and Reproductive Health Branch, develops and supports research and research training programs in contraceptive development, pelvic floors disorders and other areas of reproductive health. Major research areas include studies of: new contraceptive methods; mechanisms of action and effects of contraceptive and reproductive hormones, drugs, devices, and procedures as well as optimal formulations and dosages of contraceptive agents and spermicidal microbicides.

...

Branch-supported network:
The Contraceptive Clinical Trials Network was established in 1996 to support research on male and female contraception and to conduct clinical trials of new contraceptive drugs and devices.

Visit http://nichd.nih.gov/research/supported/Pages/cctn.aspx for more information.

http://www.nichd.nih.gov/research/supported/Pages/cctn.aspx

The CCTN was established in 1996 to support research on male and female contraception and to conduct clinical trials of new contraceptive drugs and devices.

The Network is funded through the NICHD Contreceptive Discovery and Development Branch (CDDB) (formerly the Conctraception and Reproductive Health (CRH) Branch and includes 12 sites for clinical evaluation of new female contraceptives and two sites for male contraceptives. Sites are located at university research centers and medical centers across the country. Each site employs a qualified obstetrician/gynecologist (for female-focused sites) or andrologist/urologist (for male-focused sites), study coordinator, and data/research manager, and has access to clinical facilities capable of recruiting for and conducting phase I, II, and III clinical trials.

The Network is funded through contracts and utilizes a Scientific Advisory Committee to advise on research topics and directions. The Scientific Advisory Committee is composed of outside experts in the fields of basic and clinical contraceptive research, pharmacology, and epidemiology. The Network also relies on a Statistical and Clinical Coordinating Center to monitor trials and coordinate data from all of its studies.
...


Topic Areas
The CCTN clinical field centers are selected on the basis of their capacity to conduct Phase I, II, and III trials of oral, vaginal, intrauterine, injectable, implantable, or topical contraceptive drugs and devices.

Selected research topics include (but are not limited to):

Studies of the ability of progestin- and testosterone-based topical gels to reduce gonadotropin levels and reversibly inhibit sperm production (spermatogenesis)
Studies of a progesterone receptor modulator, CDB-2914, as an emergency oral contraceptive when taken within 72 hours of unprotected intercourse
Studies of the efficacy of a novel female condom for preventing both pregnancy and sexually transmitted infections
Studies of progestin-based compounds that can prevent pregnancy without increasing the risk of blood clots and other venous thromboembolism-type conditions, especially in obese women
Studies of the use of a novel progestin- and estradiol-releasing vaginal ring for effective contraception without increasing the risk of blood clots and other venous thromboembolism-type conditions, especially in obese women
[top]

Current Sites
California Family Health Council
Case Western Reserve University
Columbia University
Eastern Virginia Medical School
Johns Hopkins University
Los Angeles Biomedical Research Institute/University of California, Los Angeles, Medical Center (male-focused)
Magee—Womens Research Institute and Foundation/University of Pittsburgh Medical Center
New York University School of Medicine
Oregon Health Sciences University
University of Cincinnati College of Medicine
University of Colorado
University of Pennsylvania Medical Center
University of Texas Southwestern Medical Center
University of Washington (male-focused)

http://www.ncbi.nlm.nih.gov/pubmed/2665354
Vaccine. 1989 Apr ;7(2):97-101.
Anti-fertility vaccines.
Talwar GP, Raghupathy R.

Source
National Institute of Immunology, Shaheed Jeet Singh Marg, New Delhi, India.


Abstract

Vaccines are under development for the control of fertility in males and females.

This review discusses developments in anti-fertility vaccines at the National Institute of Immunology, New Delhi, India. A single injection procedure for the sterilization or castration of male animals depending on the site at which the injection is given, has passed through field testing and is expected to be on the market in the near future.

Vaccines inducing antibodies against the human chorionic gonadotropin have gone through phase I trials with satisfactory results. A vaccine producing a consistently bioeffective antibody response against gonadotropin-releasing hormone is ready for phase I/II clinical trials in patients of carcinoma of prostate after due experimentation in animals and toxicology studies. Research to identify sperm antigens for incorporation into second generation vaccines is in progress.


PMID: 2665354  [PubMed - indexed for MEDLINE]

http://cfhc.org/research-center

Research Center

California Family Health Council's (CFHC) Research Center is recognized as one of the leading contraceptive research centers in the United States. For over thirty years, CFHC has conducted advanced clinical research related to the safety, acceptability and efficacy of new contraceptive methods including cervical caps, vaginal sponges, male and female condoms, IUDs, contraceptive rings, fertility monitors and microbicides.

As one of fourteen institutional members of the National Institutes of Health’s Contraceptive Clinical Trials Network, we have conducted research studies for California's Office of Family Planning, Family Health International (FHI), CONRAD, PATH, Kaiser Permanente, Merck Foundation, and The California Wellness Foundation. CFHC's Research Center also conducts research for biotech and pharmaceutical corporations to help bring new methods to market. We have published dozens of articles in peer-reviewed journals.
- See more at: http://cfhc.org/research-center#sthash.HkDHDj2a.dpuf
...
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #25 on: October 17, 2013, 01:23:59 PM »
http://factsaboutbpa.org/
Benefits & Applications

BPA is safe according to research and scientists at the Food and Drug Administration (FDA), find out more about how BPA protects us, from canned food to medical devices

http://www.cdc.gov/biomonitoring/BisphenolA_BiomonitoringSummary.html

In 1999-2000, bisphenol A was detected in 41.2% of 139 U.S. streams in 30 states (Kolpin et al., 2002). Bisphenol A can be biodegraded and does not bioaccumulate significantly in aquatic organisms. Some invertebrates may be sensitive and show reproductive effects (European Commission, 2003).

General population exposure to bisphenol A may occur through ingestion of foods in contact with bisphenol A containing materials. For small children, hand-to-mouth and direct oral contact with materials containing bisphenol A are possible. Exposure from indoor air is a small component of total exposure estimates (Wilson et al., 2007.

 In animal and human studies, bisphenol A is well absorbed orally. In humans, little free bisphenol A circulates after oral absorption due to the high degree of glucuronidation by the liver. The glucuronidated bisphenol A is excreted in the urine within 24 hours with no evidence of accumulation (Volkel et al., 2002).

Human health effects from bisphenol-A at low environmental doses or at biomonitored levels from low environmental exposures are unknown.

Occupational exposure of epoxy workers to bisphenol A dust may produce eye irritation and skin sensitization. In animal studies, bisphenol A has low acute toxicity. It is not considered a teratogen (Kim et al., 2001). Bisphenol A is rated as weakly estrogenic (Matthews et al., 2001). Some reproductive or developmental changes are observed at high doses in standard experimental animal studies (e.g., delayed vaginal opening and preputial separation) (Ema et al., 2001; Tyl et al., 2002; NTP-CERHR, 2008). Reproductive and neurodevelopmental effects of bisphenol A at low doses in animals, including environmental doses potentially relevant to humans, have been the subject of ongoing scientific reviews and study (European Commission, 2002, 2010; Gray et al., 2004; NTP, 2001; NTP-CERHR, 2007 and 2008; vom Saal and Hughes, 2005 Welshons et al., 2006; Witorsch, 2002).

Examples of recent animal studies which suggest possible low dose effects include altered development of the fetal prostate and mammary gland, inhibition of postnatal testosterone production, and changes in neurodevelopment (Akingbemi et al., 2004; Leranth et al., 2008; NTP-CERHR, 2007; Timms et al., 2005).


Biomonitoring Information
Urinary levels of bisphenol A include both conjugated and unconjugated forms and reflect recent exposure to the chemical. In the participants of NHANES 2003-2004, prevalent exposure to bisphenol A in the U.S. population was demonstrated with children, females, and lower income strata having slightly higher urinary levels (Calafat et al., 2008).

This study confirmed levels seen in an earlier smaller sample of 394 U.S. residents (Calafat et al., 2005), and slightly higher levels in children and non-Hispanic blacks is also apparent in NHANES 2005-2010 (CDC, 2012). Several previous small studies in Japanese pregnant women, Japanese university students, and Korean residents have found mean urinary bisphenol A levels to be similar or up to several times higher than those in the U.S. representative NHANES 2003-2004 subsample (Fujimaki et al., 2004; Kim et al., 2003; Ouchi and Watanabe, 2002), although one study of 73 Koreans found levels that averaged seven times higher than median levels in the NHANES 2003-2004 subsample (Yang et al., 2003; Calafat et al., 2008). Applications of certain dental sealants were shown to increase urinary levels of bisphenol A for 24 hours (Joskow et al., 2006). Hanaoka et al. (2002) studied workers with exposure to bisphenol A diglycidyl ether and found mean urinary levels of bisphenol A about double that of unexposed workers.

Finding a measurable amount of bisphenol A in the urine does not imply that the levels of bisphenol A cause an adverse health effect. Biomonitoring studies on levels of bisphenol A provide physicians and public health officials with reference values so that they can determine whether people have been exposed to higher levels of bisphenol A than are found in the general population. Biomonitoring data can also help scientists plan and conduct research on exposure and health effects.


http://www.prweb.com/releases/bisphenol_A_market/phenol_market/prweb10992205.htm
Global Bisphenol A Market to Reach 8.4 Million Metric Tons by 2018, According to a New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Bisphenol A markets. Global market for Bisphenol A is forecast to reach 8.4 million metric tons by 2018, buoyed by the robust demand for polycarbonates and epoxy resins, particularly from China and other emerging economies

San Jose, California (PRWEB) August 02, 2013

Follow us on LinkedIn – Bisphenol A (BPA), an organic chemical, has been in widespread use since the 1960s for the manufacture of polycarbonates and epoxy resins. Due to the ubiquity of downstream applications, BPA is ranked among the top industrial chemicals with the highest production volumes in the world. With the fall of the key end-use sectors during the economic recession, the end-use market for polycarbonates and epoxy resins declined significantly, thereby resulting in a loss-making scenario for Bisphenol A and phenol producers across the world. Declining BPA prices and over capacity further compounded the woes of manufacturers. However, the market quickly bounced back in sync with the recovery of the global economy.

...
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5

Offline TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 18,375
Re: Sterilization vaccine for Kangaroos - immunocontraception for people next?
« Reply #26 on: September 24, 2015, 12:59:00 PM »
bump recreated ...
Behold, happy is the man whom God correcteth: therefore despise not thou the chastening of the Almighty: For he maketh sore, and bindeth up: he woundeth, and his hands make whole ; He shall deliver thee in six troubles: yea, in seven there shall no evil touch thee. - Job 5